10QSB/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-QSB/A

    [X]        QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2005

    [  ]        TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

For the transition period from _______ to _______

01-06914

Commission File Number

Worldwide Biotech & Pharmaceutical Company
(Name of small business issuer in its charter)

Delaware	59-0950777
(State or other jurisdiction of Incorporation)	(IRS Employer Identification Number)

4 Fenghui South Road, Jie Zuo Mansion, 15th Floor, A10-11501,
Xi'an, Shaanxi, P.R. China, 710075
(Address of principal executive offices)

86-29-88193339
(Issuer's telephone number, including area code)

N/A
(Former name and former address, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

The number of shares outstanding of each of the Issuer's classes of common equity, as of the latest practicable date: As of August 15, 2005, there were 39,657,102 shares of the common stock issued and outstanding.

WORLDWIDE BIOTECH & PHARMACEUTICAL COMPANY FORM 10-QSB QUARTERLY PERIOD ENDED JUNE 30, 2005


INDEX

	Page No
PART 1. FINANCIAL INFORMATION
Item 1. Financial Statements	3
Consolidated Balance Sheet, June 30, 2005 (unaudited)	3
Consolidated Statements of Operations for the three and six month periods ended
June 30, 2005 (unaudited) and June 30, 2004 (unaudited)	4
Consolidated Statements of Stockholders' Equity for six month periods
ended June 30, 2005 and 2004 (unaudited)	5
Consolidated Statements of Cash Flows for the six month periods
ended June 30, 2005 and 2004 (unaudited)	6
Notes to Consolidated Financial Statements, June 30, 2005 (unaudited)	7
Item 2. Management's Discussion and Analysis or Plan of Operation	12
Item 3. Controls and Procedures	17
PART II. OTHER INFORMATION
Item 1. Legal Proceedings	19
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3. Defaults Upon Senior Securities	19
Item 4. Submission of Matters to a Vote of Security Holders	19
Item 5. Other Information	19
Item 6. Exhibits	19
Signatures	20

This Quarterly Report on Form 10-QSB/A of Worldwide Biotech & Pharmaceutical Company for the fiscal quarter ended June 30, 2005 is being filed for the purpose of

o revising certain disclosures and accounting treatment related to 1,400,000 shares of common stock and 3,000,000 warrants that were incorrectly valued. We initially valued these equity instruments using the fair value at date of grant and was amortizing the value over the service period. Since these shares and warrants are earned over the term of the agreement and are subject to forfeiture, the Company revised its financial statements and has accounted for these under variable accounting. Accordingly, the Company records at fair value the unearned shares and warrants each period through the term of the agreement or release from escrow.

o to reflect the Company as a development stage enterprise as defined under paragraph 8 and 9 of SFAS 7.

        This report on Form 10QSB/A supercedes in its entirety the previously filed Quarterly Report for June 30, 2005.

2

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

WORLDWIDE BIOTECH & PHARMACEUTICAL
COMPANY AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED BALANCE SHEET (RESTATED- SEE NOTE 2)
June 30,2005
(Unaudited)

ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$    219,757
Marketable securities	235,264
Prepayments and other current assets	749,002
Total Current Assets	1,204,023
PROPERTY AND EQUIPMENT (Net of accumulated depreciation of $138,634)	2,099,437
OTHER ASSET, net
	521,641
Total Assets	$ 3,825,101
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Loans payable	$ 1,751,208
Current portion of mortgages payable	34,289
Accounts payable	579,165
Due to related parties	363,507
Other current liabilities	46,510
Total Current Liabilities	2,774,679
MORTGAGES PAYABLE, less current portion	241,028
STOCKHOLDERS' EQUITY:
Common stock ($.001 Par Value; 90,000,000 Shares Authorized;
38,657,102 shares issued and outstanding)	38,657
Additional paid-in capital	9,326,434
Deficit accumulated during development stage	(7,086,492)
Less: Deferred compensation	(1,052,000)
Less: Accumulated other comprehensive loss	(417,205)
Total Stockholders' Equity	809,394
Total Liabilities and Stockholders' Equity	$ 3,825,101

See notes to consolidated financial statements

3

WORLDWIDE BIOTECH & PHARMACEUTICAL
COMPANY AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF OPERATIONS (RESTATED - SEE NOTE 2)
(Unaudited)

	For the Three Months Ended June 30, 2005            2004						For the Six Months Ended June 30, 2005            2004						For the Period from November 26, 2001 (inception) to June 30, 2005
NET REVENUES	$	--		$	--		$	--		$	--		$	--
OPERATING EXPENSES:
Research and development		11,180			43,030			53,393			68,793			693,253
Professional fees		38,607			60,472			67,468			105,248			724,163
Stock-based consulting expense		1,970,655			--			2,475,628			--			4,304,221
General and administrative		99,614			80,218			170,313			133,083			1,305,966
Total Operating Expenses		2,120,056			183,720			2,766,802			307,124			7,027,603
LOSS FROM OPERATIONS		(2,120,056	)		(183,720	)		(2,766,802	)		(307,124	)		(7,027,603	)
OTHER INCOME (EXPENSES):
Interest income		--			--			2,809			--			28,056
Interest expense		(19,672	)		(16,894	)		(66,703	)		(25,269	)		(292,942	)
Other income		90,822			--			43,791			--			159,885
Realized gain on sale of marketable securities		--			--			--			46,112			46,112
Total Other Income (Expenses)		71,150			(16,894	)		(20,103	)		20,843			(58,889	)
NET LOSS	$	(2,048,906	)	$	(200,614	)	$	(2,786,905	)	$	(286,281	)	$	(7,086,492	)
NET LOSS PER COMMON SHARE - BASIC AND DILUTED:
Net loss per common share	$	(0.05	)	$	(0.01	)	$	(0.08	)	$	(0.01	)	$	(0.21	)
Weighted Common Shares Outstanding
- basic and diluted		37,859,300			33,600,000			36,565,389			33,600,000			33,722,145

See notes to consolidated financial statements

4

WORLDWIDE BIOTECH & PHARMACEUTICAL COMPANY AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (RESTATED – SEE NOTE 2)
For the Years Ended December 31, 2005 and 2004

	Common Stock, $.001 Par Value
	Number of Shares		Amount		Additional Paid-in Capital			Accumulated Deficit	Deferred Compensation			Other Comprehensive Loss			Accumulated Total Stockholders' Equity
Balance, December 31, 2003		33,600,000		33,600		4,803,159		(2,600,621)		--			(227,432	)		2,008,706
Issuance of common stock pursuant
to share exchange agreement		1,057,102		1,057		(16,182	)	--		--			--			(15,125	)
Issuance of common shares for
services		600,000		600		779,400		--		--			--			780,000
Valuation of contingently issuable
shares		--		--		151,667		--		--			--			151,667
Value attributable to grant of
stock warrants		--		--		84,162		--		--			--			84,162
Other comprehensive loss:
Net loss
		--		--		--		(1,698,966)		--			--			(1,698,966	)
Comprehensive loss - change in
unrealized loss on marketable
securities-net of
taxes of $0		--		--		--		--		--			(98,763	)		(98,763	)
Total comprehensive loss		--		--		--		--		--			--			(1,797,729	)
Balance, December 31, 2004		35,257,102		35,257		5,802,206		(4,299,587)		--			(326,195	)		1,211,681
Issuance of common shares for
services		2,000,000		2,000		1,198,000		--		(1,200,000	)					--
Valuation of contingently shares
issued for services		1,400,000		1,400		1,526,933										1,528,333
Value attributable to grant of
stock warrants		--		--		799,295		--		--			--			799,295
Amortization of deferred
compensation										148,000						148,000
Other comprehensive loss:
Net loss						--		(2,786,905)								(2,786,905)
Comprehensive loss - change in
unrealized loss on marketable
securities-net of
taxes of $0										--			(91,010	)		(91,010	)
Total comprehensive loss		--		--						--			--			(2,877,915	)
Balance, June 30, 2005		38,657,102	$	38,657	$	9,326,434				(7,086,492	)	$	(417,205	)	$	809,394

See notes to consolidated financial statements

5

WORLDWIDE BIOTECH & PHARMACEUTICAL COMPANY AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF CASH FLOWS (RESTATED - SEE NOTE 2)
(Unaudited)

	For the Six Months Ended June 30, 2005                2004						For the Period From November 26, 2001 (inception) to June 30, 2005
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$	(2,786,905	)	$	(286,281	)	$	(7,086,492	)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization		46,567			26,686			183,832
Stock-based compensation		2,475,628			--			4,540,050
Gain on sale of marketable securities		--			(46,154	)		(46,154	)
Changes in assets and liabilities:
Prepayments and other current assets		(695,839	)		(138,775	)		(749,002	)
Accounts payable		44,230			454,775			579,165
Other current liabilities		30,165			(54,164	)		31,384
NET CASH USED IN OPERATING ACTIVITIES		(886,154	)		(43,913	)		(2,547,217	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of marketable securities		--			120,919			120,919
Investment in marketable securities		--			--			(725,514	)
Capital expenditures		(230,797	)		(980,523	)		(2,280,681	)
NET CASH FLOWS USED IN INVESTING ACTIVITIES		(230,797	)		(859,604	)		(2,885,276	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Capital contributions		--			--			3,788,166
Proceeds from loans payable		--			--			1,892,223
Proceeds from related party advances		363,507			--			363,507
Payments on loans payable		(60,911	)		(555	)		(665,506	)
Proceeds from mortgage payable		--			165,586			293,563
Payments on mortgages payable		(13,563	)		--			(18,246	)
NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		289,033			165,031			5,653,707
EFFECT OF EXCHANGE RATE CHANGES IN CASH		--			(1,457	)		(1,457	)
NET DECREASE IN CASH		(827,918	)		(739,943	)		219,757
CASH - beginning of period		1,047,675			1,342,437			--
CASH - end of period	$	219,757		$	602,494		$	219,757
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for:
Interest
	$	66,703		$	16,893		$	292,942
Income taxes
	$	--		$	--		$	--
Non-cash investing and financing activities:
Acquisition of land rights for loan payable	$	--		$	--		$	524,491

See notes to consolidated financial statements

6

NOTE 1 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB and Item 310(b) of Regulation S-B. Accordingly, the financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These consolidated financial statements should be read in conjunction with the financial statements for the year ended December 31, 2004 and notes thereto contained in the Report on Form 10-KSB of Worldwide Biotech & Pharmaceutical Company (“our Company” or the “Company”) as filed with the Securities and Exchange Commission (the “Commission”). The results of operations for the six months ended June 30, 2005 are not necessarily indicative of the results for the full fiscal year ending December 31, 2005.

The consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). The consolidated financial statements of the Company include the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated.

The Company

Worldwide Biotech & Pharmaceuticals Company (a development stage company, (the “Company” or “Worldwide”) was incorporated in Delaware in 1961 as Sun City Dairy Products, Inc., successor to a business founded in 1949. The Company operated as a holding company for various wholly owned subsidiaries that were engaged primarily in the food service marketing and distribution business.

On February 2, 1998, the Company and its prior subsidiaries filed a petition for Relief and Reorganization under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Florida (case no. 98-20679). In March 1998, the bankruptcy proceedings were converted to Chapter 7 for liquidation of the Company’s business. As a result of the conversion of the Company’s reorganization, to a case under Chapter 7, the Company’s properties were transferred to a United States Trustee on April 9, 1998 and the Company terminated its business operations. During 1998, the Bankruptcy Trustee disposed of substantially all of the assets of the Company and its subsidiaries. On June 27, 2003, the U.S. Bankruptcy Court completed the sale of the Sun City corporate shell entity.

On April 20, 2004, as amended on August 3, 2004 and effective December 16, 2004, under an Agreement and Plan of Reorganization, the Company issued 33,600,000 shares of the Company’s common stock for the acquisition of all of the outstanding capital stock of Yangling Daiying Biological Engineering Co., Ltd. (“Daiying”), a company incorporated in November 2001 in Shaanxi Province, China. For financial accounting purposes, the exchange of stock will be treated as a recapitalization of Worldwide with the former shareholders of the Company retaining 1,057,102 or approximately 5% of the outstanding stock.

Additionally, as part of the Merger, the Company amended its Articles of Incorporation, whereby it has changed its name to Worldwide Biotech & Pharmaceuticals Company. Further, the Company’s prior management resigned their respective positions with the Company and was replaced by management of Daiying.

Daiying is a biotech company that develops, manufactures, and markets diagnostic reagents, HV (Hepatitis C Viruses), medicines, vaccines and gene carriers.

7

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reporting amounts of revenues and expenses during the reported period. Significant estimates in 2005 and 2004 include the estimated useful lives of property and equipment and the valuation of marketable securities. Actual results could differ from those estimates.

Marketable securities

Marketable securities consist of investments in equity of publicly traded and non-public domestic companies and are stated at market value based on the most recently traded price of these securities at June 30, 2005. All marketable securities are classified as available for sale at June 30, 2005. Unrealized gains and losses, determined by the difference between historical purchase price and the market value at each balance sheet date, are recorded as a component of Accumulated Other Comprehensive Income in Stockholders’ Equity. Realized gains and losses are determined by the difference between historical purchase price and gross proceeds received when the marketable securities are sold.

Net loss per share

Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. Diluted loss per common share is not presented because it is anti-dilutive due to the Company’s net loss. At June 30, 2005, there were warrants to purchase 3,000,000 shares of common stock, which could potentially dilute future earnings per share.

Stock-based compensation

The Company accounts for stock options issued to employees in accordance with the provisions of Accounting Principles Board (“APB”) Opinion No. 25, “Accounting for Stock Issued to Employees,” and related interpretations. As such, compensation cost is measured on the date of grant as the excess of the current market price of the underlying stock over the exercise price. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. The Company adopted the disclosure provisions of SFAS No. 123, “Accounting for Stock-Based Compensation” and SFAS 148, “Accounting for Stock-Based Compensation –Transition and Disclosure”, which permits entities to provide pro forma net income (loss) and pro forma earnings (loss) per share disclosures for employee stock option grants as if the fair-valued based method defined in SFAS No. 123 had been applied. The Company accounts for stock options and stock issued to non-employees for goods or services in accordance with the fair value method of SFAS 123.

Revenue recognition

The Company follows the guidance of the Securities and Exchange Commission’s Staff Accounting Bulletin 104 for revenue recognition.  In general, the Company records revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured.  To date, the Company has not recognized any revenue.

8

Foreign currency translation

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Transactions and balances in other currencies are converted into U.S. dollars in accordance with Statement of Financial Accounting Standards (SFAS) No. 52, “Foreign Currency Translation,” and are included in determining net income or loss.

For foreign operations with the local currency as the functional currency, assets and liabilities are translated from the local currencies into U.S. dollars at the exchange rate prevailing at the balance sheet date. Revenues and expenses are translated at weighted average exchange rates for the period to approximate translation at the exchange rates prevailing at the dates those elements are recognized in the financial statements. Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in determining comprehensive loss.

The reporting currency is the U.S. dollar. The functional currency of the Company’s Chinese subsidiary, Daiying, is the local currency. The financial statements of the subsidiaries are translated into United States dollars using year-end rates of exchange for assets and liabilities, and average rates of exchange for the period for revenues, costs, and expenses. Net gains and losses resulting from foreign exchange transactions are included in the consolidated statements of operations and were not material during the periods presented because the Chinese dollar (RMB) fluctuates with the United States dollar. The cumulative translation adjustment and effect of exchange rate changes on cash at June 30, 2005 and 2004 was not material. As of June 30, 2005, the exchange rate for the Chinese Renminbi (RMB) was $1 US for 8.28 RMB.

Until 1994, the Renminbi experienced a gradual but significant devaluation against most major currencies, including U.S. dollars, and there was a significant devaluation of the Renminbi on January 1, 1994 in connection with the replacement of the dual exchange rate system with a unified managed floating rate foreign exchange system. Since 1994, the value of the Renminbi relative to the U.S. Dollar has remained stable and has appreciated slightly against the U.S. dollar. Countries, including the United States, have argued that the Renminbi is artificially undervalued due to China’s current monetary policies and have pressured China to allow the Renminbi to float freely in world markets. On July 21, 2005, the PRC reported that it would have its currency pegged to a basket of currencies rather than just tied to a fixed exchange rate to the dollar. It also increased the value of its currency 2% higher against the dollar, effective immediately.

If any devaluation of the Renminbi were to occur in the future, returns on our operations in China, which are expected to be in the form of Renminbi, will be negatively affected upon conversion to U.S. dollars. Although we attempt to have most future payments, mainly repayments of loans and capital contributions, denominated in U.S. dollars, if any increase in the value of the Renminbi were to occur in the future, our product sales in China and in other countries may be negatively affected.

Concentration of Credit Risk

The Company’s financial instruments consist primarily of cash, which is invested in money market accounts, marketable securities and accounts payable. The Company considers the book value of these instruments to be indicative of their respective fair value. The Company places its temporary cash investments with high credit quality institutions to limit its exposure.

NOTE 2 – RESTATEMENT OF 2005

For the six months ending June 30, 2005, the Company revised certain accounting treatment and disclosure related to 1,400,000 shares of common stock and 3,000,000 warrants that were incorrectly valued. The Company initially valued these equity instruments using the fair value at date of grant and was amortizing the value over the service period. Since these shares and warrants are earned over the term of the agreement and are subject to forfeiture, the Company revised its financial statements and has accounted for these under variable accounting. Accordingly, the Company records at fair value the unearned shares and warrants each period through the term of the agreement or release from escrow. The adjustments to the financial statements for the adjustments were as follows:

9

1.     Balance Sheet:

    a)        Additional paid-in capital decreased by $126,489 to $ 9,326,434 from $9,452,923 related to the revaluation of warrants and common stock under the variable method of accounting.

    b)        The Company’s deficit accumulated during development stage increased by $7,086,492 related to the revaluation of warrants and common stock under the variable method of accounting in the current period and for the year ended December 31, 2004.

2.     Statement of Operations:

    a)        Stock-based compensation expense decreased by $362,318 and related to the revaluation of warrants and common stock under the variable method of accounting in the current period. Net loss decreased by $362,318 to $2,786,905 from $3,149,223. Additionally, the Company added a column to the statement of operations to reflect cumulative net losses since inception and a column of operation results for three months end on June 30, 2005.

3.     Statement of Cash Flows:

    a)        For the six months ended June 30, 2005, net loss decreased by $362,318 to $2,786,905 from $3,149,223. Additionally, the Company added a column to the statement of cash flows to reflect cumulative cash flow activity since inception and a column of operation results for three months end on June 30, 2005.

NOTE 3 – OTHER ASSET

On May 15, 2002, the Company entered into an agreement with the Chinese government, whereby the Company acquired for $556,085 the rights to use certain land until May 14, 2052. The Company is amortizing this land use right over the contract period of 50 years. For the six months ended June 30, 2005 and 2004, amortization expense amounted to $5,450 and $6,563, respectively.

NOTE 4 – RELATED PARTY TRANSACTIONS

Due to related party

The Chief Executive Officer and a shareholder, from time to time, provided advances to the Company for operating expenses. These advances are short-term in nature and non-interest bearing. The amount due to these related parties at June 30, 2005 was $363,507.

NOTE 5 – STOCKHOLDERS’ EQUITY

Common stock

In 2004, in connection with a consulting agreement, the Company issued into escrow 1,400,000 shares of the Company’s common stock. On April 4, 2005, the Company issued and released to this consultant all 1,400,000 shares of common stock under the provision in the consulting agreement which is quoted as: “If a loan commitment is obtained with current rates and terms the company is obligated to take it but if refused by China Biotech the shares and warrants will be considered earned”. Since these shares were earned over the term of the agreement and were subject to forfeiture, the Company has accounted for these under variable accounting. Accordingly, the Company records at fair value the unearned shares each period through the term of the agreement. For the six months ended June 30, 2005, the Company has recognized stock compensation and additional paid-in capital of $1,528,333, respectively.

10

On May 2, 2005, the Company granted 1,000,000 shares of common stock to consultants for business development and research & development services in connection with a consulting agreement between Inline (Far East) Limited and the Company . The Company valued these shares at the quoted trading price on the date of grant of $0.60 per common share or $600,000. In connection with these shares, for the six months ended June 30, 2005, the Company recorded stock-based consulting expense of $48,000 and deferred consulting expense of $552,000, which will amortized over the service period.

On May 6, 2005, the Company granted 1,000,000 shares of common stock to consultants for business development and marketing services in connection to a consulting agreement between Creative Idea Enterprise Limited and the Company. The Company valued these shares at the quoted trading price on the date of grant of $0.60 per common share or $600,000. In connection with these shares, for the six months ended June 30, 2005, the Company recorded stock-based consulting expense of $100,000 and deferred consulting expense of $500,000, which will be amortized over the service period.

Warrants

On December 14, 2004, in connection with a consulting agreement, the Company granted 3,000,000 warrants to purchase 3,000,000 shares of common stock as follows: 500,000 must be exercised at an exercise price of $.75 per share with 4 months of the effective date of the Registration Statement on Form SB-2, 800,000 at $1.50 per share within 6 months of the same date, 900,000 at $2.50 per share within 9 months of the same date, and 800,000 at $3.50 per share within 12 months of the same date. The fair value of this warrant grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions dividend yield of -0- percent; expected volatility of 112 percent; risk-free interest rate of 4.50 percent and an expected holding periods ranging from 4 months to one year.

Since these warrants are earned over the term of the agreement and are subject to forfeiture, the Company has accounted for these under variable accounting method pursuant to EITF 96-18. Accordingly, the Company recorded at fair value the calculated value of the warrants earned at the end of each period until the warrants are earned. On April 4, 2005, the Company issued and released to this consultant all 3,000,000 warrants under the provision in the consulting agreement which is quoted as: “If a loan commitment is obtained with current rates and terms the company is obligated to take it but if refused by China Biotech the shares and warrants will be considered earned”. For the six months ended June 30, 2005, the Company recognized additional stock compensation and additional paid in capital of $799,295, respectively.

A summary of the status of the Company’s outstanding stock warrants granted for services as of June 30, 2005 and changes during the period is as follows:

	Shares	Weighted Average Exercise Price
Outstanding at December 31, 2004	3,000,000	$	2.28
Granted	--		--
Exercised	--		--
Forfeited	--		--
Outstanding at June 30, 2005	3,000,000	$	2.28
Warrants exercisable at end of year	--	$	--
Weighted-average fair value of warrants
granted during the period	2005
	$ 0.00

11

The following information applies to all warrants outstanding at June 30, 2005:

					Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices			Shares		Weighted Average Remaining Contractual Life (Years)			Weighted Average Exercise Price			Shares		Weighted Average Exercise Price
$	0	.75		500,000		0	.34		$0	.75		0	--
$	1	.50		800,000		0	.50		$1	.50		0	--
$	2	.50		900,000		0	.75		$2	.50		0	--
$	3	.50		800,000		1	.00		$3	.50		0	--
				3,000,000

NOTE 6 — OPERATING RISK

(a) Political risk

Currently, PRC is in a period of growth and is openly promoting business development in order to bring more business into PRC. Additionally PRC allows a Chinese corporation to be owned by a United States corporation. If the laws or regulations are changed by the PRC government, the Company’s ability to operate the PRC subsidiaries could be affected.

(b)     Key personnel risk

The Company’s future success depends on the continued services of executive management in China. The loss of any of their services would be detrimental to the Company and could have an adverse effect on business development. The Company does not currently maintain key-man insurance on their lives. Future success is also dependent on the ability to identify, hire, train and retain other qualified managerial and other employees. Competition for these individuals is intense and increasing.

NOTE 7 – SUBSEQUENT EVENT

On Jul 2, 2005, the Company granted 1,000,000 shares of common stock to a consultant for business development services in connection with a two-year consulting agreement between Guangdong Shengewei Media Co. Ltd. and the Company. The Company valued these shares at the quoted trading price on the date of grant of $1.02 per common share or $1,020,000, which will amortized over the service period.

Item 2. Management's Discussion and Analysis or Plan of Operation

The following analysis of our results of operations and financial condition should be read in conjunction with the financial statements of Worldwide Biotech & Pharmaceutical Company for the year ended December 31, 2004 and notes thereto contained in Report on Form 10-KSB of Worldwide Biotech & Pharmaceutical Company as filed with the Securities and Exchange Commission.

This report on Form 10-QSB contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements and from historical results of operations. Among the risks and uncertainties which could cause such a difference are those relating to our dependence upon certain key personnel, our ability to manage our growth, our success in implementing the business strategy, our success in arranging financing where required, and the risk of economic and market factors affecting us or our customers. Many of such risk factors are beyond our control.

12

Plan of Operation

The Company, by and through our wholly owned subsidiary, Yangling Daiying Biotech and Pharmaceutical Group Co., Ltd., formerly Yangling Daiying Biotech Engineering Co., Ltd. (“Daiying”), a company incorporated on November 2001 in Shaanxi Province, China, has, effective on July 12, 2005, entered into an investment contract with Xi’an Jinyou Investment Management Co., Ltd. (“Jinyou”), for the purposes of forming a new company to be formed as a limited liability company pursuant to the laws and regulations of China, said company to be known as “Shaanxi Daiying Medicine Distribution Co., Ltd.” Pursuant to the Investment Agreement, both Daiying and Jinyou will invest a total of approximately $600,000.00 U.S. Dollars of which Daiying will investment $445,000.00 for 90 percent of Shaanxi Daiying and Jinyou will invest approximately $155,000.00 for 10 percent for Shaanxi Daiying. The new company’s anticipated purpose is the wholesale distribution of traditional Chinese medicine, including Chinese medicine drink tablets, synthetic medicine, antibiotics, biotech medicine and biotech reagents; wholesale of Class II medical devices, Class III medical devices, including but not limited to, medical sewing materials and bond, medical high molecular materials and products, and disposable sterile medical devices. It takes about three months for the new company to apply for its business name at the Business Administration’s office in China, and at said time said funds shall be funded. We believe that this new distribution company will broaden and strengthen our marketing and sales channels in the near future.

We also entered into two separate Memoranda of Understanding through our subsidiary, Daiying. Neither of these transactions has at the present time effectively closed. The first agreement was entered into on January 21, 2005 with Hunan Changde Huaan Pharmaceutical Co., Ltd. (Hunan Changde). Pursuant to this agreement, a merger is contemplated wherein the Company will exchange 482,800 shares of stock for 51% control of Hunan Changde. The second agreement pursuant to Memorandum of Understanding was entered into between Daiying and Hunan Jinjin Pharmaceutical Co., Ltd. (Hunan Jinjin). Pursuant to the Memorandum of Understanding, Daiying is to exchange with various shareholders of Hunan Jinjin 211,570 shares of the Company plus approximately $410,000 in cash to acquire 65% of Hunan Jinjin. The remaining 35% would be controlled by individuals previously affiliated with Hunan Jinjin.

We are preparing to audit these two pharmaceutical companies and we expect the acquisition transactions will be closed in the third quarter of 2005. Both of Hunan Changde and Hunan Jinjin own dozens of drugs with National Drug License Numbers from SFDA in China (license for producing and sales of certain medicine freely in China). We expect increased sales and revenue generated from medicines from these two companies during the third and forth quarter of year 2005.

We intend to continue our research on Hepatitis C virus (HCV), which includes, but not limited to, screening anti-HCV medicines by using our drug screening system based on our in vitro HCV cell culturing system, developing HCV human vaccines. We intend to continue to develop and refine our ELISA kit and Rapid Test products and produce those products for sale. We will need to pursue our marketing plans to ensure both recognition of our product and to create demand. We will continue to develop, refine and pursue patents on our Traditional Chinese Medicine (TCM) products. The Company received SFDA regulation approval for “Hu Gan Tablets”, the liver-care medicine, on June 20, 2005 — National Drug License Number is Z20054104. The Company also received SFDA regulation approval for “Yi Qing Granules”, the anti-inflammation medicine, on June 30, 2005 – National Drug License Number Z20054251. The production and sales of these medicines will start from the third quarter of 2005.

13

In order to facilitate the transition from a company focused on research and development to a company that produces and sells its products and services, we will be dependent upon our ability to raise additional capital during the next 12 months. We will pursue capital raising either through conventional loans from various financial institutions or through an offering of our shares after the filing of a registration statement with the Securities and Exchange Commission. We anticipate that in order to finance our business plans and accomplish our goals, we will need to raise approximately $15,000,000 from the second quarter of year 2005 to the end of year 2006. We expect to finish the filing of a registration statement with the Securities and Exchange Commission by the end of the third quarter of 2005. The capital raise is intended to be accomplished largely through conventional loans from Chinese banks with our current property as the collateral before the registration statement is effective. We intend to utilize these funds for R & D, production, marketing and sales, administration, and acquisitions and mergers of Hunan Changde and Hunan Jinjin or more pharmaceutical companies that will foster and promote our business objectives.

Since inception, we have expended approximately $795,000 on research and product development, and $2,238,000 on plant and equipment. Based upon our current financial condition, we can satisfy our current cash requirements for seven months.

Summary of Product Research

During this period of time, we will continue product research and development including optimizing the cell culture system to provide HCV particles to facilitate biology and immunology research of HCV. We plan to develop our next generation diagnostic kit with superior sensitivity and specificity using confrontational epitopes of the Company’s antigen and corresponding specific antibodies, optimize our in-vitro drug screening, start screening some known anti-viral medicine, compound libraries, peptide libraries and extracts of TCM for discovering specific anti-HCV drugs. We will continue our research on attenuated live human vaccine for HCV. Our research team is also actively seeking new technologies and products through collaborations with other companies, research institutes and other organizations.

No Expected Equipment Purchase or Change in Number of Employees

We expect, if we are able to raise additional funds, we will purchase additional equipment, otherwise, we will not. Further, we do not expect any significant change in the number of employees unless we accomplish a merger with another company.

14

Critical Accounting Policies

A summary of significant accounting policies is included in Note 1 to the audited financial statements included Form 10-KSB as filed with the Securities and Exchange Commission for the year ended December 31, 2004. Management believes that the application of these policies on a consistent basis enables us to provide useful and reliable financial information about the company’s operating results and financial condition.

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We record property and equipment at cost. Depreciation and amortization are provided using the straight-line method over the estimated economic lives of the assets, which are from five to ten years. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred. We review the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value.

We account for stock options issued to employees in accordance with the provisions of Accounting Principles Board (“APB”) Opinion No. 25, “Accounting for Stock Issued to Employees,” and related interpretations. As such, compensation cost is measured on the date of grant as the excess of the current market price of the underlying stock over the exercise price. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. We adopted the disclosure provisions of SFAS No. 123, “Accounting for Stock-Based Compensation” and SFAS 148, “Accounting for Stock-Based Compensation -Transition and Disclosure”, which permits entities to provide pro forma net income (loss) and pro forma earnings (loss) per share disclosures for employee stock option grants as if the fair-valued based method defined in SFAS No. 123 had been applied. We account for stock options and stock issued to non-employees for goods or services in accordance with the fair value method of SFAS 123.

Results of Operations for six months ended June 30, 2005 compared to six months ended June 30, 2004

Since we were formed in November 2001, we have not earned any revenues and have incurred a net loss since our inception of $7,086,492 through June 30, 2005, including non-cash stock-based consulting expense of $4,304,221 from the issuance of common stock and granting stock warrants to consultants.

15

Operating Expenses

For the six months ended June 30, 2005, total operating expenses were $2,766,802 as compared to $307,124 for the six months ended June 30, 2004, an increase of $2,459,678, or approximately 800.9%. Included in this increase was:

o For the six months ended June 30, 2005, we incurred research and development expense of $53,393 compared to $68,793 for the six months ended June 30, 2004, a decrease of $15,400 or 22%. The decrease was due to a decrease in amounts of materials consumed in our product development.

o For the six months ended June 30, 2005, we incurred professional fees of $67,468 as compared to $105,248 for the six months ended June 30, 2004, a decrease of $37,780 or 36%. The decrease was due to a decrease in amounts paid to various consultants and professionals related to our patents and related legal matters.

o Stock-based compensation expense increased to $2,475,628 for the six months ended June 30, 2005 from $0 for the six months ended June 30, 2004. The increase in stock-based compensation expense was attributable to the valuation of common stock and warrants under the variable accounting method for common stock and warrants and for the issuance of common stock granted to consultants for business development services rendered. As of June 30, 2005, we had deferred consulting expense of $1,052,000 that will be amortized into operations in the future that will have a negative effect on our operations. We expect to incur similar stock-based compensation and consulting expense in the future.

o For the six months ended June 30, 2005, general and administrative expenses were $170,313 as compared to $133,083 for the six months ended June 30, 2004, an increase of $37,230, or approximately 28%. In the 2005 period, we incurred additional marketing fees, travel-related expenses and other administrative expenses due to the continued implementation of our business plan.

For the six months ended June 30, 2005, interest expense was $66,703 as compared to $25,269 for the six months ended June 30, 2004 and was related to an increase in borrowings.

For the six months ended June 30, 2004, we recorded a gain on sale of marketable securities of $46,112 as compared to $0 for the six months ended June 30, 2005.

For the six months ended June 30, 2005, we recorded other income of $43,791 as compared to $0 for the six months ended June 30, 2004 due to the receipt of government subsidiaries.

As a result of these factors, we reported a net loss of $2,786,905 or $.08 per share for the six months ended June 30, 2005, as compared to a net loss of $286,281 or $.01 per share for the six months ended June 30, 2004.

Results of Operations for three months ended June 30, 2005 compared to three months ended June 30, 2004

Since we were formed in November 2001, we have not earned any revenues and have incurred a net loss since our inception of $7,086,492 through June 30, 2005, including non-cash stock-based consulting expense of $4,304,221 from the issuance of common stock and granting stock warrants to consultants.

Operating Expenses

For the three months ended June 30, 2005, total operating expenses were $2,120,056 as compared to $183,720 for the three months ended June 30, 2004, an increase of $1,936,336, or approximately 1,054%. Included in this increase was:

o For the three months ended June 30, 2005, we incurred research and development expense of $11,180 compared to $43,030 for the three months ended June 30, 2004, a decrease of $31,850 or 74%. The decrease was due to a decrease in amounts of materials consumed in our product development.

o For the three months ended June 30, 2005, we incurred professional fees of $38,607 as compared to $60,472 for the three months ended June 30, 2004, a decrease of $21,865 or 36%. The decrease was due to a decrease in amounts paid to various consultants and professionals related to our patents and related legal matters.

16

o Stock-based compensation expense increased to $1,970,655 for the three months ended June 30, 2005 from $0 for the three months ended June 30, 2004. The increase in stock-based compensation expense was attributable to the valuation of common stock and warrants under the variable accounting method for common stock and warrants and for the issuance of common stock granted to consultants for business development services rendered. As of June 30, 2005, we had deferred consulting expense of $1,052,000 that will be amortized into operations in the future that will have a negative effect on our operations. We expect to incur similar stock-based compensation and consulting expense in the future.

o For the three months ended June 30, 2005, general and administrative expenses were $99,614 as compared to $80,218 for the three months ended June 30, 2004, an increase of $19,396, or approximately 24%. In the 2005 period, we incurred additional marketing fees, travel-related expenses and other administrative expenses due to the continued implementation of our business plan.

For the three months ended June 30, 2005, interest expense was $19,672 as compared to $16,894 for the three months ended June 30, 2004 and was related to an increase in borrowings.

For the three months ended June 30, 2005, we recorded other income of $90,822 as compared to $0 for the three months ended June 30, 2004 due to the receipt of government subsidiaries.

As a result of these factors, we reported a net loss of $2,048,906 or $.05 per share for the three months ended June 30, 2005, as compared to a net loss of $200,614 or $.01 per share for the three months ended June 30, 2004.

LIQUIDITY AND CAPITAL RESOURCES

At June 30, 2005, we had cash and cash equivalents of $219,757.

Net cash used in operating activities for the six months ended June 30, 2005 was $886,154 as compared to net cash used in operating activities of $43,913 for the six months ended June 30, 2004 and primarily related to our net loss.

Net cash used in investing activities for the six months ended June 30, 2005 was $230,797 as compared to net cash used in investing activities for the six months ended June 30, 2004 of $859,604. For the six months ended June 30, 2005, we used cash for capital expenditures of $230,797. For the six months ended June 30, 2004, we used cash for capital expenditures of $980,523 offset by cash provided from the sale of marketable securities of $120,919.

Net cash provided by financing activities for the six months ended June 30, 2005 was $289,033 as compared to net cash provided by financing activities for the six months ended June 30, 2004 of $165,031. For the six months ended June 30, 2005, we received net proceeds of $363,507 from related party advances offset by the repayment of loans and mortgages payable of $74,474. For the six months ended June 30, 2004, we received net proceeds of $165,586 from mortgages to acquire our land rights offset by the repayment of loans $555.

We currently have no material commitments for capital expenditures.

We are not aware of any known trends, events or uncertainties that have, or reasonably likely to have material impact on this short-term or long-term liquidity. We have no internal source of liquidity at the present time and do not generate revenue from sales, however, we intend to pursue internal sources of liquidity as explained above, through registration of various shares of stock on a registration statement to be filed with the Securities & Exchange Commission, or through traditional means of obtaining funds through various financial institutions. We are in need of additional funds to meet various anticipated capital expenditures which include research and development for drug-screening system for anti-HCV drugs and HBV vaccines, production of products for release into the market, mergers of companies that would align the Company’s business plans, and various funds to market our technology and products to create interest in the market place. We will need to raise funds either through traditional sources of financing or through the sale of stock to meet these commitments.

17

There are a number of trends, ventures, and uncertainties that are reasonably expected to have material impact on the net sales, revenues or income for continued operations. Presently, we have no income from operations. We will be unable to pursue continued research, development, production, and marketing of our product line in the event it is unable to raise sufficient funds to meet these expenses. There is no assurance that we will be able to raise sufficient funds to meet these goals. Further, we are subject to government regulation with regard to obtaining SFDA (Chinese FDA) approval for the new products, which at the present has not been accomplished. There may be delays in obtaining approval from the SFDA which would prevent us from production and/or marketing of these products. Further, we are not protected in all of its intellectual property rights and failure to do so, may allow others to infringe upon the patent.

Currently, the People’s Republic of China is in a period of growth and is constantly promoting business development in order to bring more business into China. Additionally, a Chinese corporation can be owned by United States corporation, however, the laws and regulations of China are subject to change and in the event the said change occurs, it may affect the ability of Company to operate in the People’s Republic of China.

Our future success depends on the continued services of our executive management currently in place. The loss of any of their services could be detrimental to us and could have an adverse affect on business development. Future success is also dependent on the ability to identify, hire, train, or retain other qualified employees. Competition for these individuals is intense and increasing.

Going Concern

The report from of our independent registered public accounting firm on our audited financial statements at December 31, 2004 contains an explanatory paragraph regarding doubt as to our ability to continue as a going concern. While a significant portion of our net loss for fiscal 2004 is non-cash, we do not presently generate sufficient revenue to fund our operations. The Company’s limited financial resources have prevented it from aggressively advertising or developing its product to achieve consumer recognition. In order to sustain our current operations and satisfy our current obligations, as well as to obtain sales of our products and services we will require funds for working capital. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern.

Off Balance Sheet Arrangements

The Company has no off balance sheet arrangements for the period ending June 30, 2005.

Impact of Recently Issued Accounting Pronouncements

In December 2004, the FASB issued FASB Statement No. 123R, “Share-Based Payment, an Amendment of FASB Statement No. 123” (“FAS No. 123R”).  FAS No. 123R requires companies to recognize in the statement of operations the grant- date fair value of stock options and other equity-based compensation issued to employees.  FAS No. 123R is effective beginning in the Company’s second quarter of fiscal 2006.  We are in process of evaluating the impact of this pronouncement on our financial position.

18

Item 3. Controls and Procedures

Our Chief Executive Officer and Acting Chief Financial Officer (collectively, the “Certifying Officers”) are responsible for establishing and maintaining disclosure controls and procedures for us. Based upon such officers’ evaluation of these controls and procedures as of a date as of the end of the period covered by this Quarterly Report, and subject to the limitations noted hereinafter, the Certifying Officers have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in this Quarterly Report is accumulated and communicated to management, including our principal executive officers as appropriate, to allow timely decisions regarding required disclosure.

The Certifying Officers have also indicated that there were no significant changes in our internal controls or other factors that could significantly affect such controls subsequent to the date of their evaluation, and there were no corrective actions with regard to significant deficiencies and material weaknesses.

Our management, including each of the Certifying Officers, does not expect that our disclosure controls or our internal controls will prevent all error and fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. In addition, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any systems of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of these inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

19

PART II

Item 1. Legal Proceedings

None

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In 2004, in connection with a consulting agreement, we issued into escrow 1,400,000 shares of the Company’s common stock. On April 4, 2005, these shares were released from escrow and delivered to the consultant under the provision in the consulting agreement.

On May 2, 2005, we granted 1,000,000 shares of common stock to our new consultant, Inline (Far East) Limited, for business development and research & development services. The Company valued these shares at the quoted trading price on the date of grant of $0.60 per common share or $600,000.

On May 6, 2005, we granted 1,000,000 shares of common stock to our new consultant, Creative Idea Enterprise Limited, for business development and marketing services. The Company valued these shares at the quoted trading price on the date of grant of $0.60 per common share or $600,000.

Item 3. Defaults upon Senior Securities

None

Item 4. Submission of Matters to a Vote of Security Holders

None

Item 5. Other Information

None

Item 6. Exhibits

The exhibits included in this report are indicated below.

Exhibit No.     Description of Exhibit

31.1     Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2     Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1     Certification of Chief Executive Officer Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2     Certification of Chief Financial Officer Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

20

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                 

Date: Nov 14, 2005
                 
                 
                 
                 

Date: Nov 14, 2005
                 
                 
                 
                 

Date: Nov 14, 2005
                 
                 

Date: Nov 14, 2005
                  Worldwide Biotech & Pharmaceutical Company

/s/ Wenxia Guo
- ------------------------------------
Wenxia Guo
Chief Executive Officer, Director
(Principal Executive Officer)

/s/ Peiyi Tian
- -----------------------------------
Peiyi Tian
VP, Treasurer, CFO, Director
(Principal Financial and Accounting Officer)

/s/ JianJun Liu
- -----------------------------------
JianJun Liu, Director

/s/ Huimin Zhang
- -----------------------------------
Huimin Zhang, Director

EX-31

EXHIBIT 31.1

CERTIFICATION

I, WENXIA GUO, certify that:

1.     I have reviewed this report on Form 10-QSB for the period ending June 30, 2005 of Worldwide Biotech & Pharmaceutical Company;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances, not misleading with respect to the period covered by this quarterly report;

3.     Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

4.     The small business issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and the internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the small business issuer and have:

a)         designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)         evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions after the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation;

c)         disclosed in this report any change in the small business issuer’s internal control over financial reporting that occurred during the small business issuer’s most recent fiscal quarter (the small business issuer’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and

5.     The small business issuer’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small business issuer’s board of directors (or persons performing the equivalent functions):

a)         all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and

b)         any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting.

Date: Nov 14, 2005 /s/ Wenxia Guo
Wenxia Guo, Chief Executive Officer

EX-31

EXHIBIT 31.2

CERTIFICATION

I, PEIYI TIAN, certify that:

1.     I have reviewed this report on Form 10-QSB for the period ending June 30, 2005 of Worldwide Biotech & Pharmaceutical Company;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances, not misleading with respect to the period covered by this quarterly report;

3.     Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

4.     The small business issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and the internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the small business issuer and have:

a)         designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)         evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions after the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation;

c)         disclosed in this report any change in the small business issuer’s internal control over financial reporting that occurred during the small business issuer’s most recent fiscal quarter (the small business issuer’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and

5.     The small business issuer’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small business issuer’s board of directors (or persons performing the equivalent functions):

a)         all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and

b)         any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting.

Date: Nov 14, 2005 /s/ Peiyi Tian
Peiyi Tian, Chief Financial Officer

EX-32

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Form 10-QSB of Worldwide Biotech & Pharmaceutical Company (the “Company”) on Form 10-QSB for the quarter ending June 30, 2005, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wenxia Guo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: Nov 14, 2005 /s/ Wenxia Guo
Wenxia Guo
Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Form 10-QSB of Worldwide Biotech & Pharmaceutical Company (the “Company”) on Form 10-QSB for the quarter ending June 30, 2005, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peiyi Tian , Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: Nov 14, 2005 /s/ Peiyi Tian
Peiyi Tian
Principal Accounting Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.